CN104127391B - 一种含有阿托伐他汀钙的固体药物组合物 - Google Patents
一种含有阿托伐他汀钙的固体药物组合物 Download PDFInfo
- Publication number
- CN104127391B CN104127391B CN201410380725.8A CN201410380725A CN104127391B CN 104127391 B CN104127391 B CN 104127391B CN 201410380725 A CN201410380725 A CN 201410380725A CN 104127391 B CN104127391 B CN 104127391B
- Authority
- CN
- China
- Prior art keywords
- atorvastatin calcium
- composition
- contain
- atorvastatin
- enteric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 title claims abstract description 59
- 229960001770 atorvastatin calcium Drugs 0.000 title claims abstract description 59
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 239000007787 solid Substances 0.000 title claims abstract description 13
- 239000002131 composite material Substances 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 239000003826 tablet Substances 0.000 claims abstract description 19
- 239000002662 enteric coated tablet Substances 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 238000005516 engineering process Methods 0.000 claims abstract description 6
- 239000010410 layer Substances 0.000 claims description 31
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 20
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 20
- 229960005370 atorvastatin Drugs 0.000 claims description 20
- 238000000926 separation method Methods 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 16
- 239000011248 coating agent Substances 0.000 claims description 14
- 238000000576 coating method Methods 0.000 claims description 14
- 229960004829 atorvastatin calcium trihydrate Drugs 0.000 claims description 13
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 229960001021 lactose monohydrate Drugs 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 229960003511 macrogol Drugs 0.000 claims description 9
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 claims description 8
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 8
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000001069 triethyl citrate Substances 0.000 claims description 8
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 8
- 235000013769 triethyl citrate Nutrition 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 7
- 239000002702 enteric coating Substances 0.000 claims description 7
- 238000009505 enteric coating Methods 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
- 239000002075 main ingredient Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 239000012055 enteric layer Substances 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000005030 aluminium foil Substances 0.000 claims description 3
- 239000005022 packaging material Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000007908 dry granulation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 150000002596 lactones Chemical group 0.000 abstract description 9
- 208000000112 Myalgia Diseases 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 239000012535 impurity Substances 0.000 abstract description 3
- 230000001133 acceleration Effects 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 abstract description 2
- 210000004211 gastric acid Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 210000004051 gastric juice Anatomy 0.000 description 6
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- -1 anilino- Chemical class 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OUCSEDFVYPBLLF-KAYWLYCHSA-N 5-(4-fluorophenyl)-1-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-n,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H]2OC(=O)C[C@H](O)C2)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 OUCSEDFVYPBLLF-KAYWLYCHSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000003529 anticholesteremic agent Substances 0.000 description 2
- SHZPNDRIDUBNMH-NIJVSVLQSA-L atorvastatin calcium trihydrate Chemical compound O.O.O.[Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 SHZPNDRIDUBNMH-NIJVSVLQSA-L 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229940002661 lipitor Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 150000004684 trihydrates Chemical class 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- IZVFFXVYBHFIHY-SKCNUYALSA-N 5alpha-cholest-7-en-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC[C@H]21 IZVFFXVYBHFIHY-SKCNUYALSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 208000030673 Homozygous familial hypercholesterolemia Diseases 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
原辅料 | 用量 |
片芯: | |
阿托伐他汀钙三水合物(以阿托伐他汀计) | 5g-80g |
微晶纤维素 | 50g-100g |
一水乳糖 | 25g-50g |
交联羧甲基纤维素钠 | 2g-10g |
硬脂酸镁 | 0.5g-2g |
隔离层: | |
羟丙基甲基纤维素 | 5g-10g |
聚乙二醇2000 | 0.5g-1g |
十二烷基硫酸钠 | 0.5g-1g |
肠溶包衣层: | |
尤特奇L30D-55 | 21g-42g |
柠檬酸三乙酯 | 6g-12 |
滑石粉 | 3g-6g |
共制成 | 1000片 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410380725.8A CN104127391B (zh) | 2014-08-05 | 2014-08-05 | 一种含有阿托伐他汀钙的固体药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410380725.8A CN104127391B (zh) | 2014-08-05 | 2014-08-05 | 一种含有阿托伐他汀钙的固体药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104127391A CN104127391A (zh) | 2014-11-05 |
CN104127391B true CN104127391B (zh) | 2016-08-24 |
Family
ID=51800416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410380725.8A Active CN104127391B (zh) | 2014-08-05 | 2014-08-05 | 一种含有阿托伐他汀钙的固体药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104127391B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105055357A (zh) * | 2015-09-25 | 2015-11-18 | 青岛华之草医药科技有限公司 | 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂 |
EP3370713A4 (en) * | 2015-11-06 | 2019-10-23 | Gemphire Therapeutics Inc. | TREATMENT OF MIXED DYSLIPIDEMIA |
CN108096207B (zh) * | 2017-12-29 | 2021-01-01 | 兆科药业(合肥)有限公司 | 一种罗他夫辛肠溶片的制备方法 |
CN114646709A (zh) * | 2022-05-23 | 2022-06-21 | 湖南慧泽生物医药科技有限公司 | 测定阿托伐他汀钙片体外溶出的方法及应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101134037A (zh) * | 2006-07-20 | 2008-03-05 | 杨喜鸿 | 利莫那班或其可药用盐的肠溶制剂及其制备方法 |
CN101590052A (zh) * | 2008-05-29 | 2009-12-02 | 北京奥萨医药研究中心有限公司 | 含有钙离子拮抗剂、他汀类降脂药和烟酸的药物组合物及其用途 |
-
2014
- 2014-08-05 CN CN201410380725.8A patent/CN104127391B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN104127391A (zh) | 2014-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101352426B (zh) | 一种渗透泵控释制剂组合物及其制备方法 | |
CN105263498B (zh) | 赛尼克韦罗组合物及其制备和使用方法 | |
JP2021167343A (ja) | パルボシクリブの固形剤形 | |
EP1898904B1 (en) | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation | |
CN105025886B (zh) | 地拉罗司(deferasirox)的口服制剂 | |
CN102026618B (zh) | 多巴胺激动剂的胃肠外制剂 | |
RU2616516C2 (ru) | Фармацевтическая композиция, содержащая олмесартана медоксомил и розувастатин или его соль | |
EP2422783A1 (en) | Pharmaceutical Composition | |
CN104127391B (zh) | 一种含有阿托伐他汀钙的固体药物组合物 | |
JP2009501801A (ja) | イブプロフェンとファモチジンとを含有する医薬およびその投与 | |
TWI572360B (zh) | Tiny cellulose powder | |
CN104812378B (zh) | 固体剂型 | |
HUE034393T2 (en) | Increasing the bioavailability of a drug in naltrexone therapy | |
EA031172B1 (ru) | Состав для лечения вич-инфекции на основе атазанавира и кобицистата | |
CN103251594B (zh) | 瑞格列奈二甲双胍的片剂 | |
ES2387913T3 (es) | Preparaciones de combinación de sales del ácido O-acetilsalicílico | |
CN101385731A (zh) | 治疗高脂血症的渗透泵控释制剂组合物及其制备方法 | |
KR102409102B1 (ko) | 제약 조성물 | |
WO2019018158A1 (en) | PHARMACEUTICAL COMPOSITIONS | |
JP2018158947A (ja) | 生菌含有製剤 | |
CN115887396B (zh) | 一种醋甲唑胺口崩片及其制备方法和应用 | |
CN102349906B (zh) | 阿托伐他汀钙和烟酸组合物及其制备方法 | |
RU2773029C2 (ru) | Галеновые композиции органических соединений | |
CN107811989A (zh) | 一种瑞舒伐他汀钙药物组合物及其制备方法 | |
CN101385719A (zh) | 一种治疗高血脂症的渗透泵制剂组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Ying Shuhuan Inventor after: Pi Hongjun Inventor before: The inventor has waived the right to be mentioned |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170421 Address after: 202153 Shanghai free trade zone GuoShouJing Road No. 351 Building No. 2 room A679-04 Patentee after: Shanghai Bozhi Yanxin Pharmaceutical Technology Co.,Ltd. Address before: 301700 Tianjin Guangyuan Wuqing Development Zone Wuqing Road on the south side of the Swan Garden District Building 8 Room 703 Patentee before: Li Baoqi |